Retinal sensitivity in branch retinal vein occlusion after anti-VEGF therapy

Retinal sensitivity in branch retinal vein occlusion after anti-VEGF therapy - Retinal sensitivity in BRVO after anti-VEGF therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017968

Enrollment

Registered

2015-06-19

Start date

2015-06-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Branch retinal vein occlusion

Interventions

Ranibizumab (Lucentis) intravitreal injection is performed at baseline. Measurement of the best corrected visual acuity and foveal thickness using optical coherence tomography are performed monthly. R

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Treatment naive patients of branch retinal vein occlusion with visual acuity of less than 1.0 and macular edema of more than 250 micrometers in foveal thickness.

Exclusion criteria

Exclusion criteria: Patients with history of treatment for branch retinal vein occlusion, possibility of pregnancy, allergy for ranibizumab, intraocular infection or severe inflammation will be excluded.

Design outcomes

Primary

Measure	Time frame
Retinal sensitivity at 12 months	—

Countries

Japan

Contacts

Public ContactAkira Ojima

Fukushima Medical University Department of Ophthalmology

ao@fmu.ac.jp024-548-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026